Rituximab biosimilar - Mabion

Drug Profile

Rituximab biosimilar - Mabion

Alternative Names: MabionCD20

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Mabion
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Nov 2015 Mabion is planning a phase III trial in Diffuse large B-cell lymphoma in Bosnia and Herzegovina, Croatia, Georgia, Hungary, Moldova, Poland, Romania, Serbia and Ukraine (NCT02617485)
  • 23 Jun 2015 Biosimilars market licensed to Farmak, LYFIS, Sothema Laboratories, Laboratorio LKM and Onko-Kocsel Pharmaceuticals in multiple countries (Mabion website, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top